文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

两种剂量乙型肝炎免疫球蛋白联合乙型肝炎疫苗预防乙型肝炎病毒母婴传播的效果:一项前瞻性队列研究

The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study.
PubMed 文献 · Vaccine · 2017-11-28

该前瞻性队列研究纳入中国HBsAg阳性母亲及其婴儿,比较出生后12小时内接种100 IU或200 IU乙型肝炎免疫球蛋白联合3剂10 μg乙型肝炎疫苗方案的效果。7月龄时,两组的围产期感染率分别为1.5%(8/545)和1.9%(12/632),差异无统计学意义(p=.568),抗-HBs阳性率及几何平均浓度在两组间也均无显著差异。作者认为,100 IU乙型肝炎免疫球蛋白联合乙型肝炎疫苗系列可能足以预防HBsAg阳性母亲的母婴传播。

要点

  • 7月龄围产期感染率:100 IU组1.5%(8/545)vs 200 IU组1.9%(12/632),p=.568。
  • 7月龄抗-HBs阳性率:100 IU组98.5%(529/537)vs 200 IU组98.2%(609/620),p=.704。
  • 作者认为100 IU乙型肝炎免疫球蛋白联合乙型肝炎疫苗系列可能足以预防母婴传播。

核心结论

  • 作者认为,出生时接种一剂100 IU乙型肝炎免疫球蛋白联合乙型肝炎疫苗系列可能足以预防HBsAg阳性母亲的乙型肝炎病毒母婴传播。

研究设计与样本

  • 2009年至2011年在中国前瞻性纳入HBsAg阳性母亲及其婴儿的母婴对。
  • 婴儿按母亲编号分配接受出生后12小时内一剂100 IU或200 IU乙型肝炎免疫球蛋白,随后完成3剂10 μg乙型肝炎疫苗系列。
  • 7月龄时,100 IU组545名和200 IU组632名婴儿接受接种后血清学检测,其中分别有451名和529名随访至12月龄。

主要发现

  • 7月龄围产期感染率:100 IU组1.5%(8/545)vs 200 IU组1.9%(12/632),p=.568。
  • 200 IU组一名无应答婴儿在12月龄时新发感染。
  • 7月龄抗-HBs阳性率:100 IU组98.5%(529/537)vs 200 IU组98.2%(609/620),p=.704;12月龄相应为98.2%(431/439)vs 97.1%(496/511),p=.266。
  • 7月龄抗-HBs几何平均浓度:100 IU组707.95 mIU/mL vs 200 IU组602.56 mIU/mL,p=.062;12月龄为245.47 mIU/mL vs 229.09 mIU/mL,p=.407。
  • 两组母婴和出生特征具有可比性。

关键数值与推荐

  • 7月龄围产期感染率:100 IU组1.5%(8/545)vs 200 IU组1.9%(12/632),p=.568。
  • 7月龄抗-HBs阳性率:100 IU组98.5%(529/537)vs 200 IU组98.2%(609/620),p=.704。
  • 12月龄抗-HBs阳性率:100 IU组98.2%(431/439)vs 200 IU组97.1%(496/511),p=.266。
  • 7月龄抗-HBs几何平均浓度:100 IU组707.95 mIU/mL vs 200 IU组602.56 mIU/mL,p=.062。
  • 12月龄抗-HBs几何平均浓度:100 IU组245.47 mIU/mL vs 200 IU组229.09 mIU/mL,p=.407。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: A birth dose of hepatitis B immunoglobulin (HBIG), in combination with hepatitis B vaccine (HepB), is recommended for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. However, the optimal dosage of HBIG remains to be resolved. This prospective cohort study aimed to compare the efficacy of two dosages of HBIG combined with HepB to prevent mother-to-child transmission (MTCT) of HBV. METHODS: From 2009 to 2011, we prospectively enrolled mother-infant pairs with positive maternal HBsAg in China. Infants were assigned to receive one dose of 100 IU or 200 IU HBIG within 12 h of birth according to maternal numbering, followed by completion of the 3-dose 10 μg HepB series. At 7 months, post-vaccination serologic testing (PVST) was performed in 545 and 632 infants in 100 IU and 200 IU HBIG groups, respectively, among whom, 451 and 529 were followed up to 12 months. RESULTS: Maternal and birth characteristics were comparable between infants in 100 IU and 200 IU HBIG groups. At 7 months, the rates of perinatal infection were 1.5% (8/545) and 1.9% (12/632) in 100 IU and 200 IU HBIG groups, respectively (p = .568). One non-responder infant in 200 IU HBIG group became newly infected at 12 months. The antibody to hepatitis B surface antigen (anti-HBs) positive rates were 98.5% (529/537) and 98.2% (609/620) in 100 IU and 200 IU HBIG groups at 7 months, respectively (p = .704), and the corresponding figures were 98.2% (431/439) and 97.1% (496/511) at 12 months (p = .266). The anti-HBs geometric mean concentrations were comparable between two groups at 7 months (707.95 mIU/mL vs. 602.56 mIU/mL, p = .062) and 12 months (245.47 mIU/mL vs. 229.09 mIU/mL, p = .407). CONCLUSIONS: One birth dose of 100 IU HBIG, combined with the HepB series, might be enough for preventing MTCT of HBV in infants born to HBsAg-positive mothers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wei KP, Zhu FC, Liu JX, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study. Vaccine. 2017. PMID: 29195717. doi:10.1016/j.vaccine.2017.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。